Overview

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Status:
Withdrawn
Trial end date:
2020-04-30
Target enrollment:
Participant gender:
Summary
This is a phase II clinical trial of the combination of carboplatin, eribulin, and Veliparib.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Treatments:
Carboplatin
Veliparib